Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Comment by N00bInvesT0Ron Jun 18, 2020 10:20pm
267 Views
Post# 31167658

RE:CC Pharma’s Growth Potential Had Started Commencing

RE:CC Pharma’s Growth Potential Had Started Commencing
Savage97 wrote: Last quarter, CC Pharma, saw a 50% increase in its sales of medical marijuana in March alone, the company's cannabis products overall were 13.6% more profitable than its previous quarter.  This was the fourth consecutive quarter of adjusted EBITDA growth for Aphria. The company is also doing great in achieving profitability, with a net income of CA$5.7 million during the quarter.  As for production capacity, Aphria sold 14,014 kilograms of cannabis products with an average selling price of CA$5.46 per gram g for adult-use cannabis and CA$6.41 per gram g for medical cannabis.  Aphria's gross margin for the quarter was 42.7%, the company has more than CA$515 million on its balance sheet.


That was mentionned during the conference call by the CEO, Irwin Simon. Don't forget to put the links please

https://www.fool.com/earnings/call-transcripts/2020/04/15/aphria-inc-apha-q3-2020-earnings-call-transcript.aspx

Bullboard Posts